Respiratory syncytial virus vaccine Abrysvo® will be added to the National Immunisation Program in 2025 for pregnant women

The Department of Health and Aged Care has announced that the Abrysvo® vaccine for the prevention of respiratory syncytial virus (RSV) will be added to the National Immunisation Program (NIP) for pregnant women in 2025. This vaccine is recommended for women between 28-36 weeks of pregnancy and protects their newborn child against RSV.

The Australian Government in partnership with all States and Territories will also support national access to the monoclonal antibody, Beyfortus (Nirsevimab), which provides direct protection to newborns and young children.

More information about the program, including the start date, will be announced as soon as possible.

Immunisation providers cannot claim non-NIP Abrysvo® stock under NIP claiming arrangements in advance of the program launch in 2025.

Further information:

Share Respiratory syncytial virus vaccine Abrysvo® will be added to the National Immunisation Program in 2025 for pregnant women on Facebook Share Respiratory syncytial virus vaccine Abrysvo® will be added to the National Immunisation Program in 2025 for pregnant women on Twitter Share Respiratory syncytial virus vaccine Abrysvo® will be added to the National Immunisation Program in 2025 for pregnant women on Linkedin Email Respiratory syncytial virus vaccine Abrysvo® will be added to the National Immunisation Program in 2025 for pregnant women link